Ocera: Mallinckrodt wraps up $42 million deal
Mallinckrodt has closed on its acquisition of Ocera Therapeutics Inc., a pharmaceutical firm focused on developing liver disease treatments.
Read full article »
Ocera is a biopharmaceutical company that focuses on the development and commercialization of ornithine phenylacetates.
Read more